Here is the uncomfortable thing about value analysis committees: in most hospitals, you will not be in the room when your product is decided.
University of Toledo Medical Center publishes its process, and it is worth reading closely because it is typical rather than unusual. A physician, nurse or clinical manager has to champion the request. The champion completes the trial request form. And if the request clears the first gate, it is the champion who presents to the Value Analysis Committee — not the vendor. The committee meets on the second Tuesday of each month, submissions close two weeks before, and the decision comes back within 24 hours of the meeting.
Read that sequence again and the job changes shape. You are not preparing a pitch. You are preparing someone else to give one, in a room you cannot enter, on a date you do not control, to people who will ask questions you will not hear.
What this actually costs you
The scarce resource in medical device sales is not attention. It is calendar. If a committee meets monthly and closes submissions two weeks out, a champion who is missing one document does not lose two days — they lose a month. Miss twice and you have lost a quarter against a quota that did not move.
And the stakes on the hospital side are large enough to explain why the gate exists at all. Research by Yousef Abdulsalam and Eugene Schneller, published in Health Management, Policy and Innovation using American Hospital Association survey data, put supply expenses at roughly 15% of total hospital costs and about $4,470 per admission, with medical supplies making up around 60% of that. Supply chain is the second-largest line item in most hospitals. Committees are not being obstructive. They are doing the job they were built for.
Which is why sales enablement for medical device teams has to be judged on a specific question: when your champion needs the clinical evidence, the economic model and the in-service plan at 4pm the day before submissions close, can they get all three in one place without emailing you?
The committee is not evaluating your product
It is evaluating a trade-off. The Association for Health Care Resource & Materials Management frames this as the intersection of Cost, Quality and Outcomes — the argument that these three cannot be assessed independently, and that value only appears when an organization can "deliver quality care at a more affordable cost." A device that improves outcomes and raises cost is not automatically a yes. A device that cuts cost and touches outcomes is not automatically a yes either.
UCI Health, which runs new product requests through an electronic submission portal, states its criteria plainly: clinical efficacy, product evaluation, and financial impact. Three axes. A submission strong on one and silent on the other two is a submission that gets tabled.
Most vendor material is built almost entirely for the first axis. That is the gap.
What the submission actually asks for
Requirements vary by institution, and you should always ask for the specific form rather than assuming. But across published hospital processes the same categories recur, and you can prepare all of them before you ever have a champion:
| What they ask for | What that means in practice | Who owns it at your company |
|---|---|---|
| Clinical evidence | Peer-reviewed studies, not a brochure citing them. Ideally the full text, and ideally a one-page summary of what each study did and did not show. | Medical affairs / clinical |
| Economic impact | Not unit price. Total cost including reprocessing, training, inventory carrying, waste, and any downstream effect on length of stay or reoperation. | Health economics / finance |
| Contract status | Whether the product sits on the health system's existing GPO agreement, and at what tier. If it does not, expect that to be the first question. | Contracts |
| Comparison to incumbent | An honest side-by-side against what they use today, including where the incumbent is better. Committees notice when it is missing. | Product marketing |
| Trial protocol | What will be measured, over how many cases, by whom, and what counts as success. Defined before the trial, not after. | Clinical / sales |
| In-service and training plan | Who trains which staff, on what schedule, and what happens when there is turnover six months later. | Training / enablement |
| Implementation logistics | Biomedical engineering check-in for equipment, IT review if anything connects to a network, storage footprint, disposal or reprocessing path. | Field service / ops |
Assemble that once, per product, as a single package a champion can open on a phone. Then the answer to "can you send me the evidence?" is a link, not a week of back-and-forth. This is exactly the problem one source of truth for sales content is supposed to solve, and the reason a shared drive full of folders does not solve it.
The trial is a contract, not a favor
Reps routinely treat the evaluation trial as a soft, relationship-driven step. Hospitals do not. Toledo's published rules are specific: trials run no longer than 90 days or a set number of procedures inside that window, they are conducted at no charge, and "an executed trial agreement and no charge PO must be in place prior to arrival of equipment." Equipment is checked in by biomedical engineering. If there is an IT component, IT approval has to be obtained before the agreement can even be executed.
Three things follow. Your legal team needs a trial agreement ready before you need it. Your ops team needs to know biomed will want documentation on arrival. And someone has to own the evaluation data during the trial — at Toledo, the champion tracks usage and collects evaluation data, which means if you have not agreed what "success" looks like in advance, the data that reaches the committee is whatever your champion happened to write down.
Who is in the room, and who actually decides
Two research findings should shape how you prepare a champion.
The first is who holds the pen. Bain's Front Line of Healthcare research, surveying 1,156 physicians and 154 procurement officers, found that nearly 60% of physicians said equipment purchasing was predominantly led by procurement with some physician input, and only 17% of surgeons reported a large degree of discretion. That study is a European sample and several years old, so do not quote it as a US benchmark — but nobody in the industry thinks the direction has reversed. Separately, Gartner's 2025 survey of 632 B2B buyers found buying groups of five to 16 people, with 74% showing what they call unhealthy conflict during the decision. Your champion is walking into disagreement, not consensus.
The second is what your own behavior is worth. Burns and colleagues surveyed 201 orthopedic surgeons in Pennsylvania, published in Medical Devices: Evidence and Research, and asked what drives implant choice. Patient outcomes scored 4.49 on a five-point scale. The sales rep's follow-up and thoroughness scored 4.39 — above implant longevity at 4.34. Rep knowledge scored 4.36. Consulting arrangements scored 2.10.
Thoroughness is not a soft skill in this market. It is measured, and it is rated alongside clinical performance. The rep who sends the complete packet the same afternoon is not being nice. They are being the reason the champion can present at all.
The champion's packet
If you take one thing from this: build a single, dated, shareable package per product, and hand it over rather than describing it. It should contain the seven items in the table above, plus three things reps usually forget:
- A one-page summary the champion can read in the corridor. They are presenting between cases, not preparing over a weekend.
- The two hardest objections, answered. Whatever procurement asked last time. Write the answer down so your champion does not have to improvise it.
- Your availability during the meeting window. A phone number and a promise that you will answer it. Questions come up mid-meeting, and a 20-minute reply can be the difference between a decision and a deferral.
Because you cannot walk into the room, whether the package is easy to open and share matters as much as what is in it. A trackable content sharing link tells you which documents the champion actually opened before the meeting, and which they did not — which is the closest thing to being in the room that you are going to get.
What to do differently on Monday
Call your three largest accounts and ask supply chain for two things: a copy of the new product request form, and the committee's meeting calendar with submission deadlines. Both are usually shareable, and several health systems publish them openly. Then work backwards from the next submission date instead of forwards from your last conversation.
Nothing else on this list is difficult. It is administrative work that most reps skip because it is not selling. It is the only reason some products get approved and others sit in a queue for a year.
If you are building this into how a whole team works rather than fixing it one rep at a time, we wrote about building a medical device sales training program that covers the committee as a first-class audience, and about why medical device reps need enablement in the first place.